<DOC>
	<DOCNO>NCT01254643</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , immunogenicity V503 Japanese girl age 9 15 determine whether V503 induces acceptable immune response human papillomavirus ( HPV ) strain contain vaccine . The success criterion primary analysis require point estimate seroconversion rate great 90 % 9 HPV type .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Immunogenicity 9-valent Human Papillomavirus Vaccine ( 9vHPV ; V503 ) Administered 9- 15-Year-Old Japanese Girls ( V503-008 ) .</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant good physical health Participant 's parent/legal guardian able read , understand , complete vaccine report card Participant 's parent/legal guardian agrees provide phone number followup purpose Participant sexually active plan become sexually active time Day 1 Month 7 study Participant history severe allergic reaction require medical intervention Participant thrombocytopenia coagulation disorder would contraindicate intramuscular injection Participant pregnant Participant intend donate blood time Day 1 Month 7 study Participant immunocompromised diagnosed congenital acquire immunodeficiency , human immunodeficiency virus ( HIV ) infection , lymphoma , leukemia , systemic lupus erythematosus , rheumatoid arthritis , juvenile rheumatoid arthritis , inflammatory bowel disease , autoimmune condition . Participant splenectomy Participant receive follow immunosuppressive therapy year prior enrollment : radiation therapy , cyclophosphamide , azathioprine , methotrexate , chemotherapy , cyclosporin , leflunomide ( Arava ) , tumor necrosis factor alpha ( TNFα ) antagonists , monoclonal antibody therapy , antilymphocyte serum , therapy know interfere immune response . Participant receive immune globulin product bloodderived product three month prior Day 1 vaccination , plan receive product Month 7 study Participant receive inactivated vaccine within 14 day Day 1 vaccination live vaccine within 28 day Day 1 vaccination Participant receive marketed HPV vaccine participate HPV vaccine clinical trial Participant fever ( oral temperature ≥37.8°C ) within 24 hour Day 1 vaccination Participant history positive test HPV history genital wart</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Papillomavirus vaccine</keyword>
	<keyword>Uterine cervical cancer</keyword>
	<keyword>Human Papilloma Virus infection</keyword>
</DOC>